May 26, 2021 / 02:00PM GMT
Navin Cyriac Jacob - UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
Good morning and close to good afternoon, but my name is Navin Jacob. I'm with UBS. Thank you for joining our UBS Global Healthcare Conference. I'm the senior analyst covering SMID-cap biotech and large-cap pharma here at UBS.
I'm happy to have with us for our next session, Eli Lilly and Company. And from Lilly, we have CFO, Anat Ashkenazi. Anat, thank you for joining us today.
Anat Ashkenazi - Eli Lilly and Company - Senior VP & CFO
Great. Thanks. Good to be here, Navin. Good morning, everyone.
Questions and Answers:
Navin Cyriac Jacob - UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap PharmaceuticFantastic. So we're going to have a fireside chat here with Q&A between you and me. But I do want to actually ask audience members to please feel free to participate, ask questions via the chat